Acute Coronary Syndrome

Patients evaluated for chest pain in busier emergency departments experience lower rates of death or hospitalization for acute coronary syndrome (ACS) at both 30 days and one year, according to a study published Oct. 23 in Circulation: Cardiovascular Quality and Outcomes.

Canada legalized recreational cannabis countrywide Oct. 17, triggering a national response that’s resulted in near-depletion of the country’s legal marijuana supply. But, as Canadians begin to embrace the new policy, local physician Taylor Lougheed, MD, MSc, suggests heart patients might want to consider their cardiovascular health before lighting up.

Certain antiphospholipid antibodies were detected more often after heart attacks than for age-matched controls, suggesting the markers could be used to identify patients at high risk of myocardial infarction, according to a study published Oct. 22 in the Annals of Internal Medicine.

Canadian physicians are calling for nationwide CVD screening for all competitive high school athletes, CTV News reported this week of new guidelines issued at the Canadian Cardiovascular Congress in Toronto.

Coronary artery calcium (CAC) is predictive of all-cause and cardiovascular mortality across all racial and ethnic groups, according to a study published in the Journal of the American Heart Association—but the risk of those outcomes is significantly higher across all CAC scores for black and Hispanic patients than for whites and Asians.

The FDA rejected Norvartis’ bid to expand the indications for canakinumab to include cardiovascular risk reduction among heart attack survivors, Reuters reported Oct. 18.

Patients with heart disease should aim to be physically active seven minutes for every 20 they’re sedentary to prolong life and prevent further cardiovascular damage, according to research presented at the 2018 Canadian Cardiovascular Congress in Toronto.

A novel risk score incorporating patient demographics and clinical characteristics known ahead of hospital discharge can accurately identify CVD patients at low and high risk for 90-day readmission after an initial acute MI (AMI), according to research published in the October edition of Circulation: Cardiovascular Quality and Outcomes.

A point-of-care troponin assay that yields results within about 15 minutes was equally effective at ruling out acute myocardial infarction (AMI) as a high-sensitivity troponin I test performed in a laboratory setting, researchers reported in JAMA Cardiology.

For patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease, complete revascularization is associated with greater in-hospital mortality but better long-term survival, according to an observational study published Oct. 15 in the Journal of the American College of Cardiology.

Cystatin C (Cys-C), an alternative to renal markers like creatinine and glomerular filtration rate, can effectively predict a patient’s risk for adverse CVD events after an acute coronary syndrome (ACS), researchers reported Oct. 12 in the Journal of the American Heart Association.

The FDA has approved rivaroxaban to reduce the risk of major cardiovascular events including stroke, myocardial infarction and cardiovascular death for people with chronic peripheral or coronary artery disease (PAD/CAD).